Ciara O. B.
- Country
- Ireland
- Department
- Department of Haematology/Oncology
Research Overview
- Evaluation of Trastuzumab Deruxtecan in Unresectable/Metastatic HER2-low or HER2 IHC0 Breast Cancer: A Multicenter, Open-label Study
- Comparative Evaluation of Giredestrant and Triptorelin Versus Anastrozole and Triptorelin in Premenopausal ER-Positive/HER2-Negative Early Breast Cancer
- EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA)
Data & Insights
Has run more than one trial at 211 of 493 partner sites.
Specializations
Advanced Breast Cancer Treatment
The investigator specializes in treating hormone receptor-positive (HR+), HER2-negative advanced breast cancer, particularly focusing on novel therapeutic combinations involving targeted therapies and endocrine therapy.
- Post-CDK4/6 inhibitor treatment strategies
- Advanced endocrine therapy approaches
- Metastatic breast cancer management
Early-Stage Breast Cancer Innovation
Expertise in developing treatment strategies for early-stage breast cancer, with particular emphasis on HER2-positive and hormone receptor-positive disease. The investigator explores novel approaches in neoadjuvant therapy and chemotherapy-sparing treatments.
- Personalized treatment approaches
- Targeted antibody-drug conjugates
- Response-directed therapy
Precision Medicine Applications
Focuses on implementing precision medicine strategies in breast cancer treatment, including the use of biomarker-driven therapy selection and molecular testing to guide treatment decisions.
- Recurrence score-based treatment
- ctDNA monitoring
- Hormone receptor targeting
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.